Wade’s Health Law Highlights for October 6, 2026

Fraud & Abuse Enforcement

Privacy & Data Security

Artificial Intelligence

Payers & Health Plans

Transactions & Due Diligence

Drugs & Compounding

  • FDA sent warning letters in August 2026 to five online sellers of research-use-only peptides, finding that dosing and injection content on their websites showed the products were intended for human use despite their disclaimers. The letters to NuScience Peptides, Royal Peptides, Peptide Partners, Peak Performance Peptides, and TXP Innovations (d/b/a Tex Peptides) cited tesamorelin and ipamorelin as unapproved new drugs and misbranded under the Federal Food, Drug, and Cosmetic Act, and treated the sellers’ bacteriostatic water as an unapproved drug. A June 2026 Alabama Medical Board notice bars physicians from compounding, administering, or dispensing non-FDA-approved or research-grade peptides and from delegating those acts to nurse practitioners, midwives, or physician assistants, and December 2025 Ohio Board of Pharmacy guidance states that clinics and medical spas may not lawfully possess products labeled for research only. In July 2026, a federal judge in the Northern District of Indiana sentenced Paradigm Peptides owner Matthew Kawa to 70 months in prison for introducing unapproved drugs into interstate commerce with intent to defraud, and he agreed to forfeit $5 million. Kawa had ignored FDA warning letters in 2020 and 2022 and forged certificates of analysis, and his sister, the company’s main employee, received a 16-month sentence. Source: McDermott Will & Schulte

Texas Regulatory & Policy

→